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Fluoroquinolones (FQs) are potent broad-spectrum antimicrobial agents. Since
the introduction of nalidixic acid in the 1960s, FQs have undergone extensive
synthetic and clinical development.
1 In particular, the newer generation agents are
demonstrated to be highly effective in the treatment of upper and lower respira-
tory tract infections.
2,3 Among the newer FQs, levofloxacin appears to be safe and
extremely well tolerated. It exhibits a low incidence of gastrointestinal and central
nervous system adverse events, extremely low phototoxicity, and no cardiotoxi-
city.
4 Recently, the possibility of tendinitis and tendon rupture associated with FQ
treatment has been raised.
5,6 A number of factors have been suggested to further
predispose a patient to tendon injury. The proposed factors include age over 60,
renal failure, diabetes mellitus, renal transplantation, hyperparathyroidism,
rheumatic disease, trauma, and corticosteroid treatment.
7-10 The incidence of FQ-
induced tendinopathy in a healthy population is not entirely clear but is assumed
to be low.
11,12
We present the case of a young healthy man lacking any predisposing condi-
tions who developed Achilles tendinitis following levofloxacin administration for
the treatment of community-acquired pneumonia.
A 20-year-old man presenting with a 5-day history of fever, cough, and right
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Fluoroquinolones (FQs) represent a major class of antimicrobials that have a high potential as therapeutic agents.
Although FQs are generally safe for the use as antimicrobials, they may induce tendinopathic complications such as
tendinitis and tendon rupture. A number of factors have been suggested to further predispose a patient to such injuries.
Hitherto, a few published cases on tendon disorders have implicated levofloxacin, a more recently introduced FQ.
Here, we report a patient with levofloxacin-induced Achilles tendinitis, who exhibited no known predisposing factors.
A 20-year-old man without any history of disease or medication presented with community-acquired pneumonia.
Levofloxacin was administered and 3 days later, he complained of pain in the left Achilles tendon and revealed redness
and swelling in the area. On suspecting Achilles tendinitis, levofloxacin treatment was discontinued, and the tendinitis
subsequently improved. To our knowledge, this is the first case report on FQ-induced Achilles tendinitis in Korea.
Key Words : Fluoroquinolones, tendinopathy, Achilles tendinitis, adverse reaction
Received: May 9, 2008
Revised: August 26, 2008
Accepted: August 26, 2008
Corresponding author: Dr. Jin-Soo Lee,
Department of Internal Medicine, Inha
University School of Medicine, 
7-206 Sinheung-dong 3-ga, Jung-gu, 
Incheon 400-711, Korea.
Tel: 82-32-890-3616, Fax: 82-32-882-6578
E-mail: ljinsoo@medimail.co.kr
∙The authors have no financial conflicts of
interest.
© Copyright:
Yonsei University College of Medicine 2010
This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
INTRODUCTION
CASE REPORTpleuritic chest pain was brought to the emergency depart-
ment. He had no past medical history of asthma, diabetes,
renal failure, or rheumatic disease and was not under any
medication including steroids. He was a butcher by pro-
fession and lacked any history of trauma or tendon injury
prior to admission. A physical examination revealed a
body temperature of 38.2˚C, and inspiratory crackles were
heard over the right lung field. Blood cultures were perfor-
med and expectorated sputum specimens were collected
for gram staining and culture. The laboratory findings were
as follows: white blood cells, 20,000/L (90% neutrophils);
C-reactive protein, 30.34 mg/dL (reference range, 0.00-
0.30 mg/dL); blood urea nitrogen, 8.7 mg/dL; and creati-
nine, 1.0 mg/dL. Arterial blood gas values were pH, 7.42;
pCO2, 38 mmHg; pO2, 57 mmHg; HCO3, 24 mmol/L; and
arterial oxygen saturation, 89%. The results of the serum
electrolyte investigations and the liver function tests were
normal. The serological test for HIV was negative. Simple
chest radiography revealed increased opacity in the right
middle and lower lobe along with parapneumonic effusion.
The patient was hospitalized with a diagnosis of commu-
nity-acquired pneumonia and intravenous cefminox (1 g,
three times a day) and oxygen supplements were initiated.
However, subjective and objective parameters including
respiratory symptoms, fever, partial pressure of oxygen,
and peripheral leukocyte count showed no improvement
after 2.5 days of treatment and it was decided to change the
treatment to intravenous levofloxacin (750 mg, once a day).
The patient developed sudden pain in the left ankle 3
days after the initial dose of levofloxacin was adminis-
tered. The pain was located 2-3 cm proximal to the insertion
of the left Achilles tendon at the back of the heel. Swelling
of the skin over the tendon was noted, associated with war-
mth and redness (Fig. 1). Examination revealed marked
tenderness with mild palpation of the Achilles tendon and
difficulty in moving the ankle, particularly when pushing
off with the toes. No swelling or tenderness was observed
in the other joints, particularly the shoulder or hand. We
suspected levofloxacin-induced Achilles tendinitis and
decided to discontinue levofloxacin treatment and ease the
strain to the tendon. Levofloxacin was substituted with 2 g
ceftriaxone administered intravenously once a day. The
symptoms of the left Achilles tendon improved within a
few days after levofloxacin treatment was discontinued.
Complete recovery ensued 1 month later without any sequ-
elae of tendinopathy.
Due to extensive developments in the synthesis and clinical
use of FQs, they now exhibit improved antimicrobial acti-
vity, pharmacokinetic features, and toxicity profiles.
1 Over
time, several structure-side effect relationships have been
established, and it has become standard practice to label
adverse reactions to drugs based on either their class or
individual idiosyncratic effects. Some FQ-induced side
effects are class effects and cannot be modulated by mole-
cular variation. These include GI symptoms, arthropathy,
and interactions with metal ions. However, crystalluria,
CNS effects, drug interactions, phototoxicity, and potential
genotoxicity are very sensitive to chemical modifications.
13
The first case of FQ-associated tendinopathy was report-
ed in 1983.
14 Since then, there has been a marked increase
in the number of spontaneous reports on FQ-induced
tendinopathy; however, the incidence of this condition
remains unclear. In a recent study, the overall excess risk
was 3.2 cases per 1,000 patient-years.
15 
Among newer FQ agents such as gatifloxacin, moxiflo-
xacin, and gemifloxacin, levofloxacin appears to be relati-
vely safe and very well tolerated. However, reports on
levofloxacin-induced tendinopathy are now emerging.
5,6 A
few cases of levofloxacin-associated tendon disorders have
been published, and Fleisch, et al.
16 suggested that levofloxa-
cin may have a higher incidence of drug-induced tendino-
pathy among newer FQs than previously expected. There
have been no reports on FQ-induced Achilles tendi-
nopathy in Korea. This may be due to the physician’s
unawareness of the complications involved, underreport-
ing, or racial differences in the prevalence of FQ-induced
Achilles tendinopathy. Further studies on the prevalence of
FQ-induced tendinopathy in Korea should be conducted.
It is essential to discontinue antibiotic treatment on the
first signs of symptoms and to ease the strain to the tendon.
MRI may be useful for the early detection and monitoring
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Fig. 1. Close-up photograph of the left ankle. Redness and swelling of the skin
over the Achilles tendon was noted; this finding was consistent with acute
Achilles tendinitis.
DISCUSSIONof tendinitis or tendon degeneration.
17 Moreover, once FQ-
induced tendinopathy is suspected, a patient should not be
rechallenged by quinolone treatment.
18 Considering the
potential for severe disabilities arising from tendon rupture,
physicians should be aware of the possibility of FQ-
induced tendon injury and should carefully assess the risks
of FQ treatment. The risk of tendinopathy appears to be a
class effect that is not easily ameliorated by chemical
modification
19 and it is noteworthy that up to 50% of tendon
ruptures occur without any warning signs.
7,9
In summary, we report a patient with levofloxacin-
associated Achilles tendinitis. The symptoms arose 3 days
after levofloxacin was administered, and they improved
within a few days after the treatment was discontinued.
The present case emphasizes the fact that FQ-induced
tendinopathy may occur even in the absence of predispos-
ing factors, particularly with the newer generation agent
levofloxacin. To our knowledge, this is the first case report
of FQ-associated tendinopathy in Korea.
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